Over 1,000 patients successfully treated at Apollo Proton Cancer Centre, IBA partners exclusively for Proton Beam Therapy Training.
- India to train oncologists from across the globe on Proton Beam Therapy
India / Chennai, July 7, 2023 : Since its inception in 2019, Apollo Proton Cancer Centre (APCC), the first Proton T herapy Centre in South Asia & the Middle East, has marked a definitive step ahead by making the world’s most a dvanced radiation therapy more accessible to cancer patients from across the globe. APCC has shown remarkab le expertise in Proton Beam Therapy (PBT) and has showcased excellent clinical outcomes. Over 1,000 patients have been treated with proton beam therapy at APCC.
In line with our vision to drive positive change across the world, we announce an exclusive partnership with Ion Beam Applications SA (IBA), a leading manufacturer of innovative advanced Proton Therapy System. This collab oration, which will be effective from July 15, 2023, marks a significant milestone in the field of oncology as it brin gs together two prominent names to provide specialized Proton Beam Therapy training to oncologists from acro ss the globe.
Proton Beam Therapy has emerged as a highly effective and precise radiation treatment for various types of can cers. By utilizing protons, this innovative therapy allows for targeted tumor treatment while minimizing damage to surrounding healthy tissues. The Apollo Proton Cancer Centre with its highly trained and experienced profes sionals has been at the forefront of harnessing this cutting-edge technology to deliver better outcomes and impr oved quality of life for cancer patients.
This unique collaboration between APCC and IBA aims to extend expertise in proton therapy through an advanc ed training and education program for the benefit of cancer patients and facilitate the development of cancer c are.
The center will host training programs designed to enhance the expertise of oncologists from diverse backgrou nds. By sharing their in-depth knowledge and experiences, the aim is to foster collaboration and knowledge exc hange to drive further innovation in cancer treatment across the globe.
Commenting on the collaboration, Mr Claude Dupont, Sales Director at IBA, said, “Since the opening of the Apoll o Proton Cancer Centre more than four years ago, Apollo Hospitals has shown its expertise in successfully treat ing a large variety of cancer cases. IBA is delighted to sign the final Collaboration Agreement in which Apollo Ho spitals commits to sharing its expertise in providing high-quality training and education to Proton Therapy users in Asia and other regions of the globe.”
Dr Preetha Reddy, Executive Vice Chairperson, Apollo Hospitals Enterprises Limited said, “We are pleased to an nounce our exclusive partnership with IBA for Proton Beam Therapy training at Apollo Proton Cancer Centre. T his collaboration represents a significant milestone in our mission to provide world-class cancer care and foster global advancements in the field of oncology. By joining forces with IBA, a leader in proton therapy solutions, we aim to not only train oncologists from across the world but also contribute to the wider adoption of Proton Bea m Therapy as a highly effective treatment option. We believe that this partnership will help shape the future of cancer care and enable us to make a positive impact on the lives of patients worldwide.”
Mr Dinesh Madhavan, President, Group Oncology & International, Apollo Hospital Enterprises Limited, stated, “Proton Beam Therapy one of the most advanced cancer treatments was introduced to India and South Asia by Apollo. With over 1000 patients that have benefitted from the treatment, we are now set to train clinicians, phy si cists and technologists from across the world, this will ensure that access to proton beam therapy improves an d we continue to spearhead the heal in India and heal by India.”
To meet the growing demand for Proton Beam Therapy training, the Apollo Proton Cancer Centre has outlined its future expansion plans for the benefit of oncologists from Asia and other parts of the world.
About Apollo Proton Cancer Centre
Apollo Proton Cancer Centre, the most advanced Cancer Centre and the first Proton Therapy Centre in South Asia & the Middle East and it is India’s first JCI accredited Cancer hospital. At the bedrock of APCC’s approach to treating cancer is its robust multi-disciplinary platform; highly skilled professionals who come together to fo rm a cancer management team (CMT). Each CMT is focused on delivering the best possible outcomes for its pat ients. An added feather in the cap is the recent launch of India’s first & only site-specific Robotic Oncology Prog ram.
About IBA
IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leadi ng supplier of equipment and services in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA is also a leading player in the fields of industrial sterilization, radiopharma ceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 1,600 peopl e worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and enviro nmental performance.
IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).
